deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03143985

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)

Sponsor: Koen van Besien

Conditions Multiple Myeloma
Interventions Pomalidomide Vactosertib
Updated 21 times since 2017 Last updated: May 23, 2024 Started: Jul 21, 2017 Primary completion: Feb 27, 2022 Completion: Sep 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Multiple Myeloma and is currently completed. Koen van Besien leads this study, which shows 21 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jul 2020 · 14 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jan 2022 · 8 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~May 2024 · 15 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 16 earlier versions

  1. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  4. Jan 2022 — May 2022 [monthly]

    Recruiting PHASE1

  5. May 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  6. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1

  7. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Status: Suspended → Recruiting

  8. Jul 2020 — Aug 2020 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  9. May 2019 — Jul 2020 [monthly]

    Recruiting PHASE1

  10. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE1

  11. Nov 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  12. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  13. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

    Status: Suspended → Recruiting

  14. Jun 2018 — Aug 2018 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  15. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  16. Jul 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Koen van Besien
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations